First, we showed that the CXCL5 receptor, CXCR2, which was reported to be expressed in aggressive prostate cancer epithelial cells (GS ≥ 8 and CRPC patients) [44, 45], was also expressed in our spontaneous PRAD model as well as PC3 cells (Supplemental Fig. S5e). This evidence concerns the gene CXCR2 and prostate adenocarcinoma.